Biological tissues are not static monoliths; they are dynamic populations of cells constantly dividing, mutating, and competing. To understand how a disease like cancer progresses, we must treat it as an evolutionary process. By analyzing the genetic "fingerprints" left behind by mutations, researchers can reconstruct the phylogenetic trees—the family histories—of these cell lineages. This approach allows us to see not just what a tumor is today, but how it began, how it spread, and how it might adapt to treatment.
The Logic of Truncality
The core intuition behind clonal reconstruction is the distinction between truncal and branch mutations. Imagine a tree: the trunk represents the earliest stage of growth. Any mutation that occurs in the very first cancer cell will be inherited by all its descendants. These are "truncal" mutations, and they appear in every biopsy of a tumor, regardless of where it is taken.
As the tumor grows and cells move to different locations, they acquire new, "private" mutations. These form the branches. By comparing multiple regions of a single tumor—a technique called multi-region sequencing—researchers like Ariane L. Moore and Jack Kuipers have shown that a single biopsy often misses the majority of a tumor's genetic landscape. In clear cell renal cell carcinoma, for instance, Moore et al. found that 62% of mutations were private to specific areas, including critical drivers of malignancy.
This hierarchical mapping is not limited to physical biopsies. Muhammed Murtaza and Sarah‐Jane Dawson demonstrated that "liquid biopsies"—DNA shed into the blood—can be used to track these sub-clonal shifts in real-time, providing a high-resolution view of how metastatic breast cancer evolves under the pressure of treatment Murtaza et al..
From Bulk Averages to Single Cells
Traditional sequencing "grinds up" a sample, averaging the genetic signal across millions of cells. This makes it difficult to tell if two mutations occurred in the same cell or in two different competing lineages. To solve this, researchers have moved toward single-cell DNA sequencing (scDNA-seq).
By looking at individual cells, we can observe clonal exclusivity—the phenomenon where certain mutations never appear together in the same lineage. Jack Kuipers and Katharina Jahn developed GeneAccord to statistically identify these patterns, helping to distinguish between mutations that work together and those that represent independent evolutionary experiments within the same patient Kuipers et al..
However, single-cell data is notoriously "noisy" and sparse. Tools like Phertilizer, developed by Leah L. Weber and Mohammed El-Kebir, overcome this by using a recursive partitioning approach. They combine sparse point mutations with more robust signals, like copy-number alterations, to grow an accurate clonal tree even when most of the data is missing Weber et al.. Others, like Joanna Hård, have turned to mitochondrial DNA as a natural, high-resolution barcode to track cell lineages without the need for invasive genetic engineering Hård et al..
Mapping the Geography of Evolution
Evolution doesn't just happen in a vacuum; it happens in physical space. By integrating phylogenetics with spatial transcriptomics, researchers can map how mutations spread through an organ. Andrew Erickson and colleagues discovered that histologically "benign" tissues often harbor the same aggressive mutations as nearby tumors, suggesting that the evolutionary seeds of cancer are sown long before a tumor is visible under a microscope Erickson et al..
This spatial perspective also clarifies how cancer spreads. In breast cancer, Ikram Ullah used subclonal analysis to show that distant metastases are usually seeded directly from the primary tumor or other distant sites, rather than moving linearly through the lymph nodes Ullah et al.. Similarly, Risa Burr and Ignaty Leshchiner used phylogenetic analysis to prove that some patients develop multiple primary lung tumors not because of metastasis, but because of "developmental mosaicism"—a single mutation that occurred early in embryonic development Burr et al..
Why History Matters for Treatment
Understanding the "biography" of a tumor has profound clinical implications. The order in which mutations occur can change the entire personality of a disease. Ravindra Majeti and Matthew Schwede demonstrated that in Acute Myeloid Leukemia (AML), the chronological sequence of genetic events determines how the cancer responds to therapy Majeti et al..
Furthermore, evolutionary mapping reveals the extreme "shape-shifting" capabilities of cancer. Emily Robitschek and Arnav Mehta documented cases where melanoma cells evaded immunotherapy by undergoing a complete lineage switch, transforming into a muscle-like cancer (rhabdomyosarcoma). Phylogenetic modeling confirmed these two very different-looking cancers shared a common ancestral clone, proving that resistance was driven by phenotypic plasticity rather than new mutations Robitschek et al..
By treating cancer as an evolving tree rather than a static snapshot, this research direction provides a roadmap for identifying the "pre-leukemic reservoirs" Mian et al. and ancestral drivers that must be targeted to achieve lasting cures.